Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis
Brief Summary: The purpose of this study is to assess the efficacy of ustekinumab, in adult anti-TNF(alpha) refractory participants with active radiographic axial spondyloarthritis (AxSpA), as measured by the reduction in signs and symptoms of radiographic AxSpA.


Options:
A: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: Group 2: Ustekinumab 45 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Group 2: Ustekinumab 45 mg | Arm Label: Group 3: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Group 3: Ustekinumab 90 mg | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: DRUG; Name: Group 2: Ustekinumab 45 mg; Assigned to Arm(s): Group 2: Ustekinumab 45 milligram (mg) | Intervention Type: DRUG; Name: Group 3: Ustekinumab 90 mg; Assigned to Arm(s): Group 3: Ustekinumab 90 mg
B: Arm Label: Group 1 (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Golimumab 50 mg | Arm Label: Group 2 (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Ustekinumab 45 mg, Drug: Golimumab 50 mg | Arm Label: Group 3 (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Ustekinumab 90 mg, Drug: Golimumab 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1 (Placebo), Group 2 (Ustekinumab 45 mg), Group 3 (Ustekinumab 90 mg) | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1 (Placebo), Group 2 (Ustekinumab 45 mg) | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1 (Placebo), Group 3 (Ustekinumab 90 mg) | Intervention Type: DRUG; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1 (Placebo), Group 2 (Ustekinumab 45 mg), Group 3 (Ustekinumab 90 mg)
C: Arm Label: AIN457; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457
D: Arm Label: Group 1 (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Golimumab 50 mg | Arm Label: Group 2 (ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Golimumab 50 mg | Arm Label: Group 3 (ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg, Drug: Golimumab 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1 (placebo) | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1 (placebo), Group 2 (ustekinumab 45 mg) | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1 (placebo), Group 3 (ustekinumab 90 mg) | Intervention Type: DRUG; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1 (placebo), Group 2 (ustekinumab 45 mg), Group 3 (ustekinumab 90 mg)

Answer: D